• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Chemotherapy for advanced non-small cell lung cancer patients with performance status 2.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Blackhall, Fiona H
    Bhosle, Jaishree
    Thatcher, Nick
    Affiliation
    Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uk
    Issue Date
    2005-03
    
    Metadata
    Show full item record
    Abstract
    PURPOSE OF REVIEW: A beneficial role for palliative chemotherapy in patients with advanced non-small cell lung cancer and a good performance status (ECOG 0 or 1) is now well established. In this article, we focus on the available literature for patients with a PS of 2, in whom a role for chemotherapy has yet to be defined. RECENT FINDINGS: In the past, the results of randomized trials of comparative standard platinum-based combination chemotherapy regimens have demonstrated inferior survival rates in PS 2 patients compared with those with PS 0 or 1. Consequently, a general view has emerged that the side effects of treatment outweigh the benefits, and chemotherapy has not been recommended as a standard of care. Although few studies have been designed specifically for PS 2 patients, gemcitabine, vinorelbine or taxane monotherapy, dose-attenuated platinum combination regimens, and epidermal growth factor receptor inhibitors may provide a clinical benefit with less toxicity. For example, although the median survival of PS 2 patients treated with best supportive care is 2-3 months, chemotherapy regimens are associated with median survivals ranging from 4 to 6 months. These data provide encouragement to revisit the role of chemotherapy in this group of patients. SUMMARY: There is potential with cytotoxic treatment to improve the palliative options for PS 2 patients with advanced non-small cell lung cancer. Further trials designed specifically for PS 2 patients that include measurement of symptoms, quality of life, and survival and toxicity are required to define the most active but least toxic regimens.
    Citation
    Chemotherapy for advanced non-small cell lung cancer patients with performance status 2. 2005, 17 (2):135-9 Curr Opin Oncol
    Journal
    Current Opinion in Oncology
    URI
    http://hdl.handle.net/10541/75828
    PubMed ID
    15725918
    Type
    Article
    Language
    en
    ISSN
    1040-8746
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Treatment of locally advanced non-small cell lung cancer in the elderly.
    • Authors: Gridelli C, Maione P, Rossi A, Ciardiello F, Raben D
    • Issue date: 2005 Mar
    • Targeted therapies in lung cancer.
    • Authors: Pirker R, Filipits M
    • Issue date: 2009
    • Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    • Authors: Langer CJ
    • Issue date: 2004 Mar 1
    • Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    • Authors: Chu Q, Vincent M, Logan D, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care
    • Issue date: 2005 Dec
    • A systematic overview of chemotherapy effects in non-small cell lung cancer.
    • Authors: Sörenson S, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care
    • Issue date: 2001
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.